Methods and Kits for Treating Disease By Administering Insulin-Like Growth Factor Binding Protein-2

Abstract

The present invention is directed to methods of treating Type 1-diabetes by administering a therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2. The present invention is also directed to methods treating Type 2 diabetes by administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. The present invention is further directed to methods treating insulin resistance by administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. The present invention is directed to methods of treating hepatic steatosis by administering a therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2. The present invention is also directed to methods lowering blood glucose and serum insulin in non-diabetic subjects by administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2.

What is claimed is: 
     
         1 .- 21 . (canceled) 
     
     
         22 . A method of treating hepatic steatosis comprising the step of administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2 to a subject in need thereof. 
     
     
         23 . The method of  claim 22 , wherein the subject is a mammal. 
     
     
         24 . The method of  claim 22 , wherein the subject is a human. 
     
     
         25 . The method of  claim 22 , wherein the Insulin-like Growth Factor-binding protein-2 is administered to the subject orally, topically, rectally, percutaneously, by parenteral injection, intranasally, or by inhalation. 
     
     
         26 . The method of  claim 22 , wherein the therapeutically effective amount of Insulin-like Growth Factor-binding protein-2 comprises a serum level of about 300 ng/mL to about 800 ng/mL. 
     
     
         27 .- 40 . (canceled) 
     
     
         41 . The method of  claim 22  wherein said therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2 (IGFBP-2) is provided by administration of a recombinant Insulin-like Growth Factor-binding protein-2 (IGFBP-2) or a PEGlyated recombinant IGFBP-2 protein to said subject. 
     
     
         42 . (canceled) 
     
     
         43 . The method of  claim 22 , wherein said therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2 (IGFBP-2) administered provides for a blood serum IGFBP-2 protein concentration that is at least about 2-fold to about 25-fold above a blood serum IGFBP-2 protein concentration in either: i) an untreated subject; or ii) in a healthy reference subject. 
     
     
         44 . The method of  claim 43 , wherein said therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2 (IGFBP-2) administered provides for a blood serum IGFBP-2 protein concentration that is at least about 5-fold to about 20-fold above a blood serum IGFBP-2 protein concentration in either: i) an untreated subject; or ii) in a healthy reference subject. 
     
     
         45 . The method of  claim 43 , wherein said therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2 (IGFBP-2) administered provides for a blood serum IGFBP-2 protein concentration that is at least about 8-fold to about 15-fold above a blood serum IGFBP-2 protein concentration in either: i) an untreated subject; or ii) in a healthy reference subject. 
     
     
         46 .- 53 . (canceled)